IL13 and glioblastoma: Taken together, this body of work shows that second-generation IL13-BBζ CAR T cells are superior to first-generation CAR T cells in controlling glioblastoma (GBM) xenotransplants in mice (6), and that intraventricular delivery of IL13-BBζ CAR T cells provides improved control of multifocal disease as compared with intratumoral or intravenous delivery (6).